Kindred Bio canine arthritis drug fails clinical trial

Shares of Kindred Biosciences (NASDAQ:KIN) plummet 34% on robust volume in response to the company's disclosure that its lead product candidate, CereKin (diacerein), an interleukin-1 inhibitor for the control of pain and inflammation associated with osteoarthritis in dogs, failed to achieve its primary endpoint in a clinical trial.

The failure was due to a higher-than-expected placebo response rate and statistical variability. In the high dose (20 mg/kg) cohort, the response rate was comparable to human studies but the dropout rate was too high to achieve statistical significance.

From other sites
Comments (2)
  • jfadelle
    , contributor
    Comments (9) | Send Message
    Huge market over expected.
    20 Aug 2014, 10:16 PM Reply Like
  • ejg80s
    , contributor
    Comments (107) | Send Message
    These guys are juggling too many plates and they should just focus on a couple of sure hit trials or else they are going to run out of $$. Stock hit today is a wake up call to the company! At least their stock based compensation costs will go down!
    21 Aug 2014, 06:01 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs